Altimmune

ALT NASDAQ
2.360
-0.100
-4.07%
Closed 16:00 06/18 EDT
Open
2.500
Prev Close
2.460
High
2.580
Low
2.350
Volume
327.06K
Avg Vol (3M)
839.14K
52 Week High
36.25
52 Week Low
1.700
% Turnover
1.47%
Market Cap
52.56M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Altimmune ALT stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Altimmune, Inc., formerly Pharmathene, Inc., is a clinical-stage immunotherapeutic company. The Company focuses in development of medical counter measures against biological and chemical threats. The Company is involved in development of two next generation anthrax vaccines. It has two proprietary platform technologies, RespirVec and Densigen. Its candidates include NasoVAX, HepTcell, NasoShield and Oncosyn. NasoVAX is an intranasally administered recombinant influenza vaccine. The Company has completed Phase I clinical trials of NasoVAX. HepTcell is being tested as an immunotherapy for patients chronically infected with the hepatitis B virus. NasoShield is an intranasal, single-dose anthrax vaccine designed to provide rapid, stable protection after one intranasal administration. Oncosyn is being developed as a cancer immunotherapeutic product candidate. Oncosyn targets multiple tumor antigens simultaneous to prevent tumor escape.
MORE >

Recently

Name
Price
%Change